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Abstract
Introduction: Pheochromocytomas and paragangliomas are rare tumours deriving from chromaffin cells of adrenal medulla or paraganglia. 
They are usually benign, but 10–35% of them present malignant behaviour. The aim of the study was to evaluate the efficacy and safety 
of 131-I MIBG therapy in malignant pheochromocytoma /paraganglioma patients (MPPGL).
Material and methods: Eighteen patients (7 women and 11 men) were included in this study. Between 2002 and 2016 they underwent 
131-I MIBG therapy because of MPPGL, and their medical data were analysed retrospectively. Clinical indications for the treatment in-
cluded progressive disease or massive tissue involvement independently of disease progression. Tumour response for the first time was 
assessed three months after the last treatment, according to Response Evaluation Criteria in Solid Tumours criteria and by 131-I MIBG scans.
Results: The mean single dose used was 7.25 GBq (196 mCi) and mean cumulative dose 33.08 GBq (894 mCi). In two (11%) patients complete 
tumour response was achieved. In one (6%) patient partial response was obtained. In 13 (72%) patients stable disease was observed. In two 
(11%) patients progression was diagnosed three months after treatment discontinuation. In the whole studied group the progression-free 
survival time was 85 months and overall five-year survival was 87%.
Conclusions: Radionuclide treatment with use of 131-I MIBG may be an effective form of palliative treatment for patients with inoperative 
neoplasm spread or progressive disease, or patients requiring alleviation of symptoms. (Endokrynol Pol 2018; 69 (3): 246–251)
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Streszczenie
Wstęp: Guzy chromochłonne i przyzwojaki są rzadkimi guzami wywodzącymi się z tkanki chromochłonnej rdzenia nadnerczy i ciałek 
przyzwojowych. Zwykle są to nowotwory łagodne, jednak w 10–35% mogą prezentować potencjał złośliwy. Celem pracy była ocena 
skuteczności i bezpieczeństwa leczenia radioizotopowego 131-I MIBG w złośliwych guzach chromochłonnych i przyzwojakach podda-
wanych terapii w pojedynczym ośrodku onkologicznym.
Materiał i metody: Do badania włączono 18 pacjentów (7 kobiet, 11 mężczyzn). Dokumentacja medyczna pacjentów ze złośliwymi 
guzami chromochłonnymi i przyzwojakami, którzy zostali poddani leczeniu radioizotopowemu 131-I MIBG w latach 2002–2016 została 
przeanalizowana retrospektywnie. Kliniczne wskazania do terapii obejmowały progresję choroby (5 pacjentów), dużą masę nowotworu 
niezależnie od dynamiki choroby (13 pacjentów). Odpowiedź na leczenie oceniano po raz pierwszy po 3 miesiącach przy użyciu tomografii 
komputerowej według kryteriów Response Evaluation Criteria in Solid Tumors oraz scyntygrafii 131-MIBG .
Wyniki: Średnia pojedyncza dawka radiofarmaceutyku zastosowana podczas leczenia wynosiła 7,25 GBq (196 mCi), średnia skumulo-
wana 33,08 GBq (894 mCi). Średni czas obserwacji pacjentów po leczeniu wynosił 78 miesięcy (zakres: 7–197 mies.). U 2 pacjentów (11%) 
uzyskano całkowitą remisję, u 1 pacjenta (6%) częściową remisję, a u 13 pacjentów (72%) obserwowano stabilną chorobę. U 2 pacjentów 
(11%) 3 miesiące po zakończeniu leczenia potwierdzono progresję choroby. W całej analizowanej grupie czas wolny do progresji wyniósł 
85 miesięcy, a 5-letnie przeżycie 87%.
Wnioski: Leczenie radioizotopowe z użyciem 131-I MIBG może być efektywną metodą leczenia paliatywnego złośliwych guzów 
chromochłonnych lub przyzwojaków w przypadku choroby nieoperacyjnej, rozsianej, z potwierdzoną progresją, czy też u pacjentów 
wymagających leczenia objawowego. (Endokrynol Pol 2018; 69 (3): 246–251)
Słowa kluczowe: guz chromochłonny, przyzwojak, leczenie radioizotopowe 131-I MIBG
Introduction
Pheochromocytomas and paragangliomas are rare 
tumours deriving from chromaffin cells of adrenal 
medulla or paraganglia, able to synthesise, store, and 
secrete catecholamines or their metabolites. They are 
usually benign, but 10–35% of them present malignant 
behaviour [1, 2]. Several biochemical, morphologi-
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cal, and molecular markers of malignancy have been 
investigated, but the only reliable criterion generally 
agreed is the presence of distant metastases in non-
chromaffin tissues [3]. Complete surgical excision of 
the tumour is the treatment of choice. In the presence 
of neoplasm spread palliative treatment is the only op-
tion [4]. Among them, 131-I MIBG therapy, introduced 
into the treatment in 1984, is the most widely used. 
Metaiodobenzylguanidine (MIBG) is a substrate for 
transmembrane noradrenaline transporter (NAT) ac-
tively captured and stored in presynaptic sympathetic 
nerve terminals (and also in tumour cells). Its coupling 
with 131-I enables tumour cell damage by the action of 
beta particles [5, 6]. About 60% of metastatic foci show 
avid uptake of 131-I MIBG, and approximately 30% of 
them demonstrate objective response to the therapy 
[4, 7]. An additional 40% of the tumours remain stable 
[6, 8]. There are no strict recommendations about the 
doses and schedules used because only a few studies, 
with small patient groups, have been published. 
The aim of the study was to evaluate the efficacy and 
safety of 131-I MIBG therapy in malignant pheochro-
mocytoma/paraganglioma patients treated in a single 
endocrine oncology centre. 
Material and methods
Eighteen patients (7 women and 11 men) were in-
cluded in this study. Between 2002 and 2016 they 
underwent 131-I MIBG therapy because of malig-
nant pheochromocytoma or paraganglioma tumours 
(MPPGL), and their medical data were analysed ret-
rospectively. In 10 (55%) patients pheochromocytoma 
was diagnosed, and in eight (45%) cases paraganglio-
ma. In 15 (83%) patients the diagnosis was confirmed 
in histological examination after primary tumour resec-
tion, and in the remaining three (17%) in histological 
analysis of specimens obtained on core-needle biopsy 
or explorative laparotomy. The presence of metastases 
was confirmed by radiologic modalities (CT or MRI) 
and radionuclide imaging (131I or 123I MIBG scans). 
Hormonal activity of the tumour was assessed by 
measuring total or fractionated metanephrines in 24-h 
urinary excretion. The results of 24-h urinary excretion 
measurements were available for 14 patients. Clinical 
characteristics of whole group are shown in Table I. 
Genotyping of the main PPGL susceptibility genes 
(RET, VHL, SDHB, SDHD, MAX, and TMEM 127) was 
performed in each patient. The genetic status of the 
group is illustrated in Table II.
Once the extent of disease was evaluated, therapy 
options were discussed on the multidisciplinary board 
team meetings. Patients without the possibility of using 
loco regional procedures and with avid MIBG uptake 
Table I. Clinical characteristics of the cohort
Tabela I. Charakterystyka kliniczna analizowanej grupy
Diagnosis 
pheochromocytoma 
paraganglioma
No of patients (%)
10 (56%)
8 (45%)
Gender
female
male
No. of patients (%)
7 (39%)
11 (61%)
Hormonal activity of the tumour 
present
absent
No of patients (%)
8/14 (57%)
6/14 (43%)
Localisation of metastases
soft tissues (lymph nodes, lung, liver)
bones exclusively or with soft tissues
No. of patients (%)
8 (44%)
10 (56%)
Time from diagnosis to metastases 
occurrence
mean
range
Years
 
5.2
0-20
Age at the time of treatment
mean
range
Years
43.6
11-84
Prior treatment
resection of primary lesion
loco regional surgery (metastases or local 
recurrence removal)
chemotherapy
radiotherapy 
No of patients (%)
15 (83%)
3 (17%)
 
2 (11%)
1 (6%)
Table II. Genetic status of patients with MPPGL treated 
with use of 131-MIBG
Tabela II. Wyniki analizy DNA u pacjentów ze złośliwymi 
guzami chromochłonnymi i przyzwojakami leczonych 
radioizotopowow przy użyciu MIBG 131-I
Genetic status No. of patients (%)
SDHB 3 (17%)
RET 1 (6 %)
VHL 1 (6%)
NF1 1 (6%)
No mutation found 11 (65%)
on diagnostic imaging were qualified for radionuclide 
treatment with the use of 131I-MIBG. Clinical indications 
for the treatment included progressive disease (five 
patients) or massive tissue involvement independently 
of disease progression (13 patients). 
Complete clinical evaluation, blood count, and 
serum chemistry analyses were conducted before the 
therapy procedure. 
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Sodium perchlorate or potassium iodide were used 
for thyroid protection.
A standard 131-I MIBG protocol included five cours-
es of 7.4 GBq (200 mCi) activity repeated in 12-week 
intervals. In some patients, individual adjustments were 
made. 131-I MIBG was administered intravenously 
over a two-hour period. Patients were isolated until the 
radiation dose rate measured at 1 m decreased to less 
than 20 uSv/h. At that time post-therapy whole body 
scintigraphy was performed.
Tumour response for the first time was assessed after 
the last treatment by CT according to Response Evaluation 
Criteria in Solid Tumours (RECIST) criteria and by 131-I 
MIBG scans evaluated on the basis of the interpretation 
of an assessing nuclear medicine specialist. Urinary 
metanephrines were measured only in patients with 
elevated values prior to treatment. At least 50% decrease 
in diurnal excretion was defined as post-therapeutic 
hormonal response.
Adverse events were evaluated according to Com-
mon Terminology Criteria for Adverse Events 3.0. 
Clinical, biochemical, and radiological status was 
under surveillance annually. If needed, radionuclide 
imaging was performed. 
Overall survival was determined by using the 
Kaplan-Meyer method.
Results
The mean single dose used was 7.25 GBq (196 mCi) 
and mean cumulative dose 33.08 GBq (894 mCi). Mean 
time of follow-up after treatment was 78 months (range 
7–197 months).
Complete response was obtained in two patients 
with lymph node and bone metastases. There was no 
disease relapse during follow-up (respectively, 100 and 
197 months).
Partial response was observed in one patient, who 
remained stable for 60 months. Subsequently, because 
of progression, peptide receptor radionuclide therapy 
(PRRT) was performed.
In 13 (72%) patients stable disease was the best re-
sponse to 131-I MIBG therapy. Among the group of 13 
patients with stable disease assessed three months after 
the last treatment course, four patients were progressive 
prior to treatment. In the remaining nine patients pro-
gression was not confirmed prior to 131-MIBG therapy. 
In the group of patients progressive prior to treatment 
three remained stable in the follow-up period (14–150 
months), in one we observed extension of the disease after 
85 months. In the cohort of patients with stabilisation of 
disease after 131-I MIBG therapy and without progression 
prior the treatment eight remained stable in follow-up 
(4–127 months) and one progressed after 34 months.
Progressive disease three months after treatment 
discontinuation was observed in two patients: SDHB 
mutation male carrier with lymph node metastases 
(progressive also prior treatment); and sporadic 
pheochromocytoma in a male patient with metastases 
localised in bones and soft tissues. 
Results of the 131-I MIBG treatment are illustrated 
in Figure 1. 
Although all patients underwent analysis of genetic 
status, a relatively small number of patients with muta-
tion (Tab. I) enabled statistical analysis of differences in 
response to the 131-I MIBG treatment. The most common 
mutation found was SDHB. The characteristic of this 
group and efficacy of treatment is summarised in Table III.
In the whole studied group, the progression-free 
survival time was 85 months and five-year survival was 
87%. The Kaplan-Meyer survival curve is illustrated in 
Figure 2.
Hormonal response to the radionuclide therapy was 
obtained in all eight patients with hormonal activity 
confirmed before treatment. Normalisation of metane-
phrines excretion was seen in four (50%) of them. In 
seven patients hormonal response was accompanied by 
stabilisation of the tumour extent after treatment, and 
in one patient with partial tumour response.
In eight patients we achieved very good palliative 
effect. In six of them a decrease in blood pressure was 
obtained as well as alleviation of headaches, heart 
Figure 1. Early results of the 131-I MIBG treatment (evaluated 
3 months after the last treatment course) 
CR — complete response, PR — partial response, SD — stable 
disease, PD — progressive disease
Rycina 1. Wczesne efekty leczenia radioizotopowego przy użyciu 
131-I MIBG (oceniane 3 miesiące po podaniu ostatniej aktywności)
CR — całkowita remisja, PR — częściowa remisja, SD — stabilna 
choroba, PD — progresja
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palpitations, and weakness. In two patients with mas-
sive painful bone metastases the pain was significantly 
resolved and return of locomotive functions was ob-
served. 
In 44% of patients adverse events affecting the 
haematological system were observed; however, only 
in 11% of patients they reached the third degree of toxi-
city according to Common Terminology Criteria for Adverse 
Events, and in all cases except one, they were temporary. 
In one patient nausea and vomitus occurred during 
the second course of therapy, treated successfully with 
metoclopramide and ondansetron. In one patient we 
observed a short-term exacerbation of arterial hyperten-
sion with the need of drug dose adjustment. In spite 
of thyroid protection, hypothyroidism was observed 
in almost one third of patients, leading to necessity of 
levothyroxine substitution. Hypogonadism confirmed 
by hormonal tests appeared in one female patient. In 
a young man with varicose veins of spermatic cord, the 
post therapeutic hormonal data of gonadal axis were 
normal but azoospermia was diagnosed. Toxicity of 
the radionuclide treatment is summarised in Table IV.
Discussion
The rarity of malignant pheochromocytoma and para-
ganglioma tumours substantially limits the possibility 
of evaluation of treatment results. Available data refer-
ring to the use of 131-I MIBG for treatment of MPPGL 
in single centres include several series containing 5–49 
patients [6, 9–17]. Among these studies only one was 
a prospective II phase clinical trial [6]. The treatment 
regimens and doses of radionuclide differ in all series, 
which hamper comparison. In our Department the 
mean single dose was 7.25 GBq (196 mCi) and mean 
cumulative dose 33.08 GBq (894 mCi). Mean cumulative 
activity in analysed series reported in literature range 
from 6.9 GBq (186 mCi) to 39.4 GBq (1065 mCi), with the 
Table III. Characteristics of patients with SDHB mutation
Tabela III. Charakterystyka pacjentów z mutacją SDHB
Patient 
number
Progression prior 131-I 
MIBG treatment
Therapy 
results
Time to progression after 
treatment (months)
Follow-up time/survival
1 No SD 17 Disqualified from chemotherapy because of heart failure and 
died 32 months after treatment
2 Yes PD 0 Qualified for external radiotherapy and remains alive 77 
months after treatment
3 No SD Without progression under 
surveillance
81 months, still alive
Figure 2. Kaplan-Meyer survival curve
Rycina 2. Krzywa przeżycia Kaplana-Meyera
Table IV. Summary of 131-MIBG treatment adverse events
Tabela IV. Podsumowanie działań niepożądanych leczenia 
radioizotopowego przy użyciu 131-I MIBG
Toxicity No of patients (%)
Haematological
Leukopaenia
gr. 1
gr. 2
gr. 3
gr. 4
Anaemia
Thrombocytopaenia
gr . 1
gr. 2
gr. 3
gr. 4
1 (6%)
2 (11%)
1 (6%)
0 (0%)
0 (0%)
2 (11%)
0 (0%)
1 (6%)
0 (0%)
Hypothyroidism 4 (22%)
Hypogonadism
Azoospermia and infertility
1 (6%)
1 (6%)
Exacerbation of arterial hypertension 1 (6%)
Nausea and vomiting 1 (6%) 
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number of infusions ranging from one to 12 [6, 9–17]. 
Different criteria assessing tumour response used in 
different centres are another limitation influencing the 
comparison of data. Complete response was reported 
in 0–38% of patients [6, 9–17], and partial response 
ranged from 17 to 47% [6, 9–17]. Using the RECIST 
criteria in our study, we observed complete response in 
two patients (11%) and partial response in another one 
(6%). This objective tumour response was obtained in 
MPPGL with metastases localised in bones and lymph 
nodes. The existing data from a comprehensive review 
reported by Loh et al. show better response to 131-I 
MIBG therapy in patients with soft tissue metastases 
compared with those with bone metastases [18]. This 
discrepancy is difficult to interpret because we observed 
only two cases. In our study, in the majority of patients 
we achieved stabilization of the disease (72%), which is 
close to the results from other centres in which stable 
disease was observed in 17–60% of patients [6, 9–17].
In most studies patients were selected to 131-I MIBG 
therapy independently of disease dynamics. The pro-
gressive disease was the inclusion criterion only in one 
study [16]. In our cohort five patients had confirmed 
progression prior treatment. In four of them partial 
response or stable disease was achieved. Differences 
in opinions about when to initiate the treatment in 
MPPGL impede the solution of dilemma if stable disease 
after 131-MIBG treatment is a result of therapy or a con-
sequence of natural tumour behaviour. This limitation 
also hampers the interpretation of progression-free sur-
vival (PFS). The progression-free survival we reported 
is 85 months. Gedik et al. reported progression-free 
survival time of 23.1 months [15]. Shilkrut et al. reported 
PFS of 28.5 months [17]. Only a few studies assessed 
overall survival (OS). Gonias et al. reported five-year 
overall survival of 64% in a phase II study of high-dose 
131-I MIBG therapy for patients with metastatic pheo-
chromocytoma and paraganglioma [6]. In Rutherford’s 
study five-year overall survival was 68% [19]. In our 
study five-year overall survival was 87% It is worth 
to underlining that five-year overall survival for MP-
PGL patients assessed historically, when radionuclide 
therapy was not available, was estimated as 44% [20].
There are limited data on the influence of genetic 
status affecting efficacy of radionuclide treatment. 
In a study by Gonias et al. 12 patients out of 24 who 
underwent genetic testing had confirmed SDHB mu-
tation. SDHB-positive patients achieved complete or 
partial response significantly more often; however, 
SDHB status was not a significant predictor of overall 
survival. They concluded that lack of influence on OS 
despite better response to the treatment may be the 
result of the aggressive natural behaviour of MPPGL 
with SDHB mutation [6]. In our group there were three 
(21%) patients with SDHB mutation. This small number 
enabled statistical analysis of differences in response to 
the 131-I MIBG treatment.
In our cohort hormonal response was observed in 
all patients with elevated metanephrines prior to 131-I 
MIBG therapy, which was accompanied by stable dis-
ease or partial tumour response. Data concerning the 
influence of hormonal response on overall survival are 
equivocal. In a phase II study of high-dose 131-I MIBG 
therapy Gonias et al. reported no predictive value of 
hormone response to overall survival [6]. In contrast, 
Safford et al. proved the significance of hormonal re-
sponse as a predictor of survival [14].
As well as reduction of measurable disease and 
achieving elongation of progression-free survival, an-
other goal of radionuclide treatment is relieving patients 
of symptoms. In our cohort 44% of patients benefited 
and we observed alleviating of catecholamine excess 
symptoms and complaints related to tumour burden. In 
a meta-analysis by Loh et al. symptomatic improvement 
was observed in 76% of patients [18]. In single-centre 
studies symptomatic response was seen in 50–89% of 
patients [15, 17, 19, 21].
The most frequent toxicity of 131-I MIBG treatment 
observed in our study and reported from other centre 
was haematological. Leukopaenia and thrombocyto-
paenia affected 50% of our cohort, but mostly there 
were first- and second-degree temporary events. In 
studies on the use of similar radionuclide activities, 
haematological toxicity occurred in 8–40% patients 
[9–17]. Only in study with high dose 131-I MIBG (me-
dian cumulative dose 0.44 GBq (12 mCi/kg) haemato-
logical toxicity was severe, affecting more than 80% of 
patients [6]. Despite the use of sodium perchlorate or 
potassium iodide for thyroid protection, one third of 
our patients developed hypothyroidism. In a phase II 
clinical trial of high-dose 131-I MIBG therapy only 6.1% 
of patients suffered from hypothyroidism after radio-
nuclide treatment, but in a study by Brans et al. 40% 
developed hypothyroidism [6, 22]. Temporary increase 
of blood pressure demanding significant modification 
of hypotensive therapy was observed by us in one 
patient during the treatment course, despite the use of 
alfa-blockers. The same was reported by Sakahara et al. 
[13]. We did not observe renal failure, which is in line 
with literature data [6, 9–17].
We report one case of hypogonadism confirmed 
by hormonal assessment and one case of infertility 
with ambiguous background. In a phase II clinical 
trial of high-dose 131-I MIBG therapy, four patients 
out of 49 developed hypogonadism [6]. Rutherford 
et al. observed two ovarian failures among a group of 
22 patients treated with a median cumulative dose of 
20.13 GBq (544 mCi).
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Secondary malignancies are rare toxicities after 131- 
-MIBG treatment. Myelodysplasia and acute myelocytic 
leukaemia were observed with 4% incidence in a study 
by Gonias with high-dose therapy. In our report there 
was one case of lymphoma in an 84-year-old female. 131-
I MIBG therapy with a cumulative dose of 4.4 GBq (1200 
mCi) divided into six courses was her only oncologic 
treatment besides surgical procedure. Lymphoma ap-
peared four years after radionuclide therapy. Although 
radiation is a known risk factor for secondary malignan-
cies, its relation to 131-I MIBG treatment is equivocal.
Conclusions
Therapy of malignant pheochromocytoma and para-
ganglioma is still a challenge. Radionuclide treatment 
with 131-I MIBG may be an effective form of pallia-
tive treatment for patients with inoperative neoplasm 
spread or progressive disease, or for patients requiring 
alleviation of symptoms. Toxicity with use of a single 
dose not exceeding 7.4 GBq (200 mCi) and median 
cumulative dose below 37 GBq (1000 mCi) is moderate 
and mostly temporary. The decision of when to initiate 
the treatment remains under debate. 
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